Comparison of HBV-specific CD8+T cell reactivity across the patients with chronic HBV infection,cirrhosis or hepatocellular carcinoma
10.13431/j.cnki.immunol.j.20240046
- VernacularTitle:慢性乙型肝炎及HBV相关肝硬化和肝细胞癌患者间HBV特异性CD8+T细胞反应活性的比较分析
- Author:
Mengying ZHU
1
;
Ruixue JI
;
Pinqing LI
;
Yuqi MA
;
Damin JIAO
;
Fangping YUE
;
Yandan WU
;
Jie QIU
;
Xiling FU
;
Jiabao CHANG
Author Information
1. 210003,南京市第二医院肝病科
- Keywords:
Chronic hepatitis B;
Cirrhosis;
Hepatocellular carcinoma;
Antigen-specific T cell detection
- From:
Immunological Journal
2024;40(4):365-374
- CountryChina
- Language:Chinese
-
Abstract:
This study was performed to investigate the features of HBV-specific CD8+T cell reactivity in patients with chronic hepatitis B(CHB),HBV-induced liver cirrhosis(LC)or hepatocellular carcinoma(HCC).A total of 124 CHB patients,36 LC patients,and 114 HCC patients were enrolled in this study.The reactive HBV-specific CD8+T cells in peripheral blood were enumerated using an innovative ELISPOT system.In addition,19 CHB patients and 20 HCC patients were longitudinally monitored with an interval of 3-5 months.Data showed that the numbers of reactive HBV-specific CD8+T cells in CHB group were not significantly different from that in LC group,but obviously lower than that in HCC group(P=0.009 9),especially HBsAg-,HBpol-and HBe/cAg-specific CD8+T cells.In CHB group,the patients with normal ALT level,AST level,or low HBV-DNA load showed significantly more reactive HBV-specific CD8+T cells than the patients with abnormal ALT level,abnormal AST level,or high HBV-DNA load.Furthermore,the duration of NUCs treatment had an impact on the HBV-specific CD8+T cell reactivity in CHB patients,while different NUCs at the same treatment duration did not bring different reactivity of HBV-specific T cells.In LC group,the HBeAg-positive patients presented much more reactive HBV-specific CD8+T cells than the HBeAg-negative patients did.In HCC group,the numbers of reactive HBV-specific CD8+T cells in the patients with normal AFP level or normal DCP level were significantly higher than that in the patients with abnormal AFP level or abnormal DCP level.Longitudinal monitoring results showed that HBV-specific CD8+T cell reactivity displayed a slow upward trend in the CHB patients undergoing NUCs treatment,and an obvious increasing in the HCC patients undergoing combined treatment of targeted drugs and immunotherapy.Taken together,the features of HBV-specific CD8+T cell reactivity are distinct among the CHB,LC and HCC patients,and are influenced by virological indicators,tumor markers and treatment regimens.Therefore,more attention should be paid to the changes of HBV-specific CD8+T cell reactivity during clinical treatment.
